Another high-potential possibility is the targeting of the pleiotropic cytokine IL-6, which proved to be successful in an experimental autoimmune encephalomyelitis model, and a clinical trial is also on the way [193]. The gene discussed is IL6; the disease is experimental autoimmune encephalomyelitis.